Encourages Congress to pass critically important healthcare provisions
WASHINGTON, DC (December 18, 2024) – The Association for Accessible Medicines, the trade association for generic and biosimilar manufacturers, today commented on the positive policy developments within the Congressional continuing resolution. “The healthcare provisions in the year-end funding bill are a double win—streamlining patient access to affordable generic and biosimilar medicines and saving the government money,” said John Murphy III, President and CEO of AAM
“AAM applauds Congress for including these measures in the CR, and strongly encourages passage. Among many positive reforms included in the package, this bill will help patients by bringing down costs of medication by streamlining FDA processes, prohibiting patent manipulation in the biosimilars market, arresting the arcane pricing practices of pharmacy benefit managers, and ensuring the hard-working members of the government healthcare system remain on point to look out for the interests of the American patient. These provisions will not only bring lower-cost medicines to patients sooner, but they will also increase efficiencies in government programs and approvals and reduce federal health care spending for the long term. Thank you to Congressional leaders and committee chairs for working hard on behalf of all American patients.”
2024 U.S. Generic & Biosimilar Medicines Savings Report:
https://accessiblemeds.org/resources/blog/2024-savings-report
MEDIA CONTACT:
About AAM The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.
About the Biosimilars Council The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.